Anti-inflammatory activity of methyl palmitate and ethyl palmitate in different experimental rat models

Toxicology and Applied Pharmacology

Volumn 264, Issue 1, 2012, Pages 84-93

  Saeed, Noha M ^a   El Demerdash, Ebtehal ^b   Abdel Rahman, Hanaa M ^a   Algandaby, Mardi M ^c   Al Abbasi, Fahad A ^c   Abdel Naim, Ashraf B ^b  

^a Egyptian Russian University in Egypt   (Egypt)

^b Ain Shams University   (Egypt)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Ethyl palmitate; Inflammation; Methyl palmitate

Indexed keywords

ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MYELOPEROXIDASE; PALMITIC ACID ETHYL ESTER; PALMITIC ACID METHYL ESTER; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; EAR EDEMA; ENDOTOXEMIA; HISTOPATHOLOGY; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PAW EDEMA; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DINOPROSTONE; DISEASE MODELS, ANIMAL; EDEMA; ENDOTOXEMIA; INFLAMMATION; LIPOPOLYSACCHARIDES; LIVER; LUNG; MALE; NEUTROPHIL INFILTRATION; NF-KAPPA B; PALMITATES; PALMITIC ACIDS; PEROXIDASE; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; RATTUS;

EID: 84865995984     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2012.07.020     Document Type: Article

References (50)

1. Ajuebor M.N., Singh A., Wallace J.L. Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279:G238-G244.
2. Ali S., Mann D.A. Signal transduction via the NF-kappaB pathway: a targeted treatment modality for infection, inflammation and repair. Cell Biochem. Funct. 2004, 22:67-79.
3. Ali A., Warkentin T., Bardossy L., Goldsmith C., Blajchman M. Platelet concentrates stored for 5days in a reduced volume of plasma maintain hemostatic function and viability. Transfusion 1994, 34:44-47.
4. Ali A.M., Warkentin T.E., Bardossy L., Goldsmith C.H., Blajchman M.A. Platelet concentrates stored for 5days in a reduced volume of plasma maintain hemostatic function and viability. Transfusion 1994, 34:44-47.
5. Balkwill F. Cytokines-soluble factors in immune responses. Curr. Opin. Immunol. 1988, 1:241-249.
6. Bone R.C. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit. Care Med. 1996, 24:163-172.
7. Bradley P.P., Priebat D.A., Christensen R.D., Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 1982, 78:206-209.
8. Cai P., Kaphalia B.S., Ansari G.A. Methyl palmitate: inhibitor of phagocytosis in primary rat Kupffer cells. Toxicology 2005, 210:197-204.
9. Cao S., Zhang X., Edwards J.P., Mosser D.M. NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J. Biol. Chem. 2006, 281:26041-26050.
10. Conning D.M., Heppleston A.G. Reticuloendothelial activity and local particle disposal. A comparison of the influence of modifying agents. Br. J. Exp. Pathol. 1966, 47:388-400.
11. Cowper K.B., Currin R.T., Dawson T.L., Lindert K.A., Lemasters J.J., Thurman R.G. A new method to monitor Kupffer-cell function continuously in the perfused rat liver. Dissociation of glycogenolysis from particle phagocytosis. Biochem. J. 1990, 266:141-147.
12. Dayer J.M. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology 2003, 42:ii3.
13. El-Demerdash E. Anti-inflammatory and antifibrotic effects of methyl palmitate. Toxicol. Appl. Pharmacol. 2011, 254:238-244.
14. Elsharkawy A.M., Mann D.A. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 2007, 46:590-597.
15. Ghosh S., Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109(Suppl.):S81-S96.
16. Goulet J.L., Snouwaert J.N., Latour A.M., Coffman T.M., Koller B.H. Altered inflammatory responses in leukotriene-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:12852-12856.
17. Gross S., Gammon S.T., Moss B.L., Rauch D., Harding J., Heinecke J.W., Ratner L., Piwnica-Worms D. Bioluminescence imaging of myeloperoxidase activity in vivo. Nat. Med. 2009, 15:455-461.
18. Hagemann T., Lawrence T., McNeish I., Charles K.A., Kulbe H., Thompson R.G., Robinson S.C., Balkwill F.R."Re-educating" tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 2008, 205:1261-1268.
19. Hagiwara S., Iwasaka H., Hasegawa A., Hidaka S., Uno A., Ueo K., Uchida T., Noguchi T. Filtration leukocytapheresis therapy ameliorates lipopolysaccharide-induced systemic inflammation in a rat model. J. Surg. Res. 2010, 171:777-782.
20. Hisadome M., Terasawa M., Goto K., Kawazoe Y., Okumoto T. Stimulation of phagocytic activity of leukocytes and macrophages by traxanox sodium in mice and rats. Jpn. J. Pharmacol. 1989, 49:275-284.
21. Jakubowski A. S-nitroso-human-albumin: a new therapeutic approach in endotoxic shock. Pol. Arch. Med. Wewn. 2009, 119:501-504.
22. Jean-Baptiste E. Cellular mechanisms in sepsis. J. Intensive Care Med. 2007, 22:63-72.
23. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
24. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 2002, 3:221-227.
25. Klebanoff S.J. Myeloperoxidase. Proc. Assoc. Am. Physicians 1999, 111:383-389.
26. Krishnamurti C., Maglasang P., Rothwell S. Reduction of blood loss by infusion of human platelets in a rabbit kidney injury model. Transfusion 1999, 39:967-974.
27. Kudo K., Hagiwara S., Hasegawa A., Kusaka J., Koga H., Noguchi T. Cepharanthine exerts anti-inflammatory effects via NF-kappaB inhibition in a LPS-induced rat model of systemic inflammation. J. Surg. Res. 2011, 171:199-204.
28. Laskin D.L., Weinberger B., Laskin J.D. Functional heterogeneity in liver and lung macrophages. J. Leukoc. Biol. 2001, 70:163-170.
29. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
30. Majdalawieh A., Ro H.S. Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages. Mediators Inflamm. 2010, 2010:823821.
31. Mantawy E.M., Tadros M.G., Awad A.S., Hassan D.A., El-Demerdash E. Insights antifibrotic mechanism of methyl palmitate: impact on nuclear factor kappa B and proinflammatory cytokines. Toxicol. Appl. Pharmacol. 2012, 258:134-144.
32. McVey D.C., Vigna S.R. The capsaicin VR1 receptor mediates substance P release in toxin A-induced enteritis in rats. Peptides 2001, 22:1439-1446.
33. Medzhitov R. Inflammation 2010: new adventures of an old flame. Cell 2010, 140:771-776.
34. Miyaura C., Inada M., Matsumoto C., Ohshiba T., Uozumi N., Shimizu T., Ito A. An essential role of cytosolic phospholipase A2alpha in prostaglandin E2-mediated bone resorption associated with inflammation. J. Exp. Med. 2003, 197:1303-1310.
35. Palu, A. K., West, B., Jensen, C. J., Su, C., Zhou, B. N., and Story, S. P. (2006). Morinda citrifolia as a 5-Lipoxygenase inhibitor. Google Patents.
36. Peter B., Gauthier O., Laib S., Bujoli B., Guicheux J., Janvier P., van Lenthe G.H., Muller R., Zambelli P.Y., Bouler J.M., Pioletti D.P. Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats. J. Biomed. Mater. Res. A 2006, 76:133-143.
37. Robinson S.M., Mann D.A. Role of nuclear factor kappaB in liver health and disease. Clin. Sci. (Lond.) 2010, 118:691-705.
38. Sarkar S., Khan M.F., Kaphalia B.S., Ansari G.A. Methyl palmitate inhibits lipopolysaccharide-stimulated phagocytic activity of rat peritoneal macrophages. J. Biochem. Mol. Toxicol. 2006, 20:302-308.
39. Sealey J.E., Itskovitz-Eldor J., Rubattu S., James G.D., August P., Thaler I., Levron J., Laragh J.H. Estradiol- and progesterone-related increases in the renin-aldosterone system: studies during ovarian stimulation and early pregnancy. J. Clin. Endocrinol. Metab. 1994, 79:258-264.
40. Serhan C.N., Ward P.A., Gilroy D.W. Fundamentals of Inflammation 2010, Cambridge Univ Pr.
41. Smith J.A. Neutrophils, host defense, and inflammation: a double-edged sword. J. Leukoc. Biol. 1994, 56:672-686.
42. Streetz K.L., Luedde T., Manns M.P., Trautwein C. Interleukin 6 and liver regeneration. Gut 2000, 47:309-312.
43. Stuart A., Davidson A.E. Effect of simple lipids on antibody formation after injection of foreign red cells. J. Pathol. Bacteriol. 1964, 87:305-316.
44. Sugimoto Y., Narumiya S. Prostaglandin E receptors. J. Biol. Chem. 2007, 282:11613-11617.
45. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
46. Terragno N.A., Terragno D.A., Pacholczyk D., McGiff J.C. Prostaglandins and the regulation of uterine blood flow in pregnancy. Nature 1974, 249:57-58.
47. Tonelli G., Thibault L., Ringler I. A bio-assay for the concomitant assessment of the antiphlogistic and thymolytic activities of topically applied corticoids. Endocrinology 1965, 77:625-634.
48. Winter C.A., Risley E.A., Nuss G.W. Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc. Soc. Exp. Biol. Med. 1962, 111:544-547.
49. Yamamoto Y., Gaynor R.B. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 2001, 107:135-142.
50. Yeh C.H., Lin Y.M., Wu Y.C., Lin P.J. Inhibition of NF-kappa B activation can attenuate ischemia/reperfusion-induced contractility impairment via decreasing cardiomyocytic proinflammatory gene up-regulation and matrix metalloproteinase expression. J. Cardiovasc. Pharmacol. 2005, 45:301-309.